Equity Overview
Price & Market Data
Price: $30.91
Daily Change: +$0.72 / 2.33%
Daily Range: $30.41 - $31.02
Market Cap: $1,434,334,336
Daily Volume: 4,712
Performance Metrics
1 Week: 12.15%
1 Month: -1.18%
3 Months: 3.00%
6 Months: 80.89%
1 Year: 403.2%
YTD: -4.28%
Company Details
Employees: 63
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.